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Abstract 
Background and purpose 
Familial hypercholesterolemia (FH) is a common autosomal dominant disease leading 
to increased level of serum low-density lipoprotein cholesterol and risk of coronary 
heart disease (CHD). Whether FH increases the risk of cerebrovascular disease 
including ischemic stroke is debated. Accordingly we studied the incidence of 
cerebrovascular disease in a cohort of persons with genetically verified FH compared 
to the entire Norwegian population, and examined whether persons in this cohort with 
previous cohort had increased risk of cerebrovascular disease. 
 
Methods 
Incidence rates of hospitalization for cerebrovascular disease (among 3144 persons 
with FH) and ischemic stroke (among 3166 persons with FH) were estimated by linkage 
of FH persons to CVDNOR; a nationwide database of cardiovascular disease 
hospitalizations (2001-2009). We calculated standardized incidence ratios (SIRs), and 
used Cox regression to estimate hazard ratios (HRs). 
 Results 
A total of 46 cases (19 women and 27 men) of cerebrovascular disease were observed 
in the cohort of persons with FH,  with no increased risk of cerebrovascular disease 
compared to the general population (SIR=1.0, 95% confidence interval (CI) (0.8-1.4)). 
Total number of ischemic strokes in the cohort of persons with FH was 26 (9 women 
and 17 men), with no increased risk compared to the general population (SIR=1.0, 
95%CI (0.7-1.5)).  Prior CHD significantly increased cerebrovascular disease risk in 
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Stroke is an important cause of disability and death worldwide,1 and there are several 
risk factors for stroke such as hypertension, carotid artery atherosclerosis and smoking.2 
Atherosclerosis is an underlying factor for stroke, and accordingly, low-density 
lipoprotein (LDL)-cholesterol lowering therapy is important in both primary and 
secondary prevention of cerebrovascular diseases including stroke.3  
 
Persons with heterozygous familial hypercholesterolemia (FH) have increased levels of 
LDL-cholesterol from birth,4 and increased risk of premature coronary heart disease 
(CHD) and heart failure due to the increased LDL-cholesterol load.5–7 With the 
increased risk of atherosclerosis, the risk of stroke in FH patients is expected to be high. 
However, whether the risk of stroke in FH patients is increased has been debated and 
previous studies have yielded inconsistent results.8, 9  
 
Our aim was to investigate risk of cerebrovascular disease including ischemic stroke in 
a genetically verified cohort of persons with FH in comparison with the risk in the entire 
Norwegian population. In addition, we aimed to examine whether previous 
hospitalization for CHD was associated with the risk of cerebrovascular disease, 
including ischemic strokes.  
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Material and methods 
The study was approved by the Regional Committee for Medical and Health Research 
Ethics, South-East Norway, and is a cohort study of persons with FH identified from 
the Unit for Cardiac and Cardiovascular Genetics (UCCG) Registry linked to the 
Norwegian Cause of Death Registry and the Cardiovascular Disease in Norway 
(CVDNOR) project database. Data used in this project cannot be made available for 
researchers without new approvals because of data protection legislation in Norway.  
All patients with genetically diagnosed FH in Norway are included in the National 
UCCG Registry after written informed consent. Prior to the registry linkage all 
patients received a letter and were offered to be removed from the list and not 
participate in the registry linkage. 
 
  
An incident event of cerebrovascular disease was defined as a hospitalization with 
cerebrovascular disease as main or secondary diagnosis or death with cerebrovascular 
disease as the underlying cause, without any prior hospitalizations with cerebrovascular 
disease during the past seven years. Patients were followed from inclusion in the FH 
registry until the first occurrence of cerebrovascular disease, death or 31st December 
2009, whichever came first. Incident events of ischemic stroke were defined in the same 
manner.  
We calculated incidence rates and standardized incidence ratios (SIRs with 95% 
confidence intervals (CIs)) for cerebrovascular disease and ischemic stroke using 
incidence rates for the total  Norwegian population as reference rates. The association 
between CHD and risk of cerebrovascular disease was analyzed by including CHD as 
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a time-dependent covariate in a Cox regression, reported as hazard ratios (HRs) with 




In total, 3144 persons with FH (46.6% men, mean (standard deviation (SD)) age at 
inclusion was 39.9 years (14.9)) were included in analyses of cerebrovascular disease 
and compared to the age, sex and calendar year adjusted Norwegian population. The 
analyses of ischemic stroke included 3166 persons with FH (46.5% men, mean (SD) 
age at inclusion 39.2 years (14.3)). Total follow-up was more than 18 500 person years.  
 
A total of 46 cases of cerebrovascular disease were observed in persons with FH, 19 
women and 27 men, and no significant increased risk of cerebrovascular disease was 
found (Table 1).  When ischemic strokes were analyzed, 26 ischemic strokes were 
observed (9 women and 17 men), and again, no significant increased risk in persons 
with FH (Table 1).  
 
In the group of 46 patients with cerebrovascular disease, 23 (50%) had previous CHD, 
11 women (57.9%) and 12 men (44.4%). In Cox regression analyses of the association 
between CHD and cerebrovascular disease we found a significant interaction between 
sex and CHD (pinteraction=0.04). In separate analyses for men and women, a significant 
association between previous CHD and risk of cerebrovascular disease was found in 
women (HR=3.29, 95% CI (1.20-9.00)) but not in men (HR=1.03, 95% CI (0.45-2.37)). 
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Discussion 
In our cohort of 3170 genetically verified persons with FH and more than 18 500 
person-years of follow-up, there was no increased incidence of cerebrovascular disease 
or ischemic stroke compared to the entire population of Norway, and as far as we know, 
this is the largest data set to date investigating this. Acknowledging the contribution of 
age to the risk of cerebrovascular disease, mean age at inclusion was relatively low in 
the our cohort. 
The finding of no increased risk of cerebrovascular disease and ischemic stroke in 
persons with high LDL-cholesterol from birth is interesting, and challenges the concept 
of LDL-cholesterol being a major risk factor for cerebrovascular disease and ischemic 
stroke. Importantly, in the present cohort, the risk of CHD was more than fourfold 
increased during the same period of time.6 A Mendelian randomization study recently 
found that persons with lifelong low levels of PCSK9 and LDL-cholesterol had lower 
risk of CHD, but with no effect on ischemic stroke.10 This has questioned the relation 
between LDL-cholesterol and ischemic strokes. Indeed, much of the support for the 
LDL-cholesterol hypothesis regarding risk of ischemic stroke is based upon the reduced 
incidence of stroke found in landmark statin trials.11 However, the largest published 
meta-analysis of statin trials found only a small reduction in stroke risk among statin-
treated men, and no effect on stroke incidence  in women.11  
The results of most previous studies on cerebrovascular disease and stroke in persons 
with FH are in agreement of our findings.9,12,13 In contrast, Toell et al recently 
demonstrated increased prevalence of ischemic strokes and transient ischemic attacks 
in persons with FH,8   however, with FH defined by clinical criteria and not genetic 
criteria. 
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Previous hospitalization for CHD increased the risk of cerebrovascular disease in 
women in the present study but surprisingly not in men, this finding warrants further 
investigation as the sample is quite small. 
 
Limitations 
Registration of actual lipid levels and medication, was not possible in the present study, 
and should be addressed in future studies of stroke in persons with FH. Given the 
registry-based study design, we did not have information on lifestyle factors. Selection 
bias is always an important issue in register studies. Importantly, all physicians in 






In this large cohort of 3170 genetically verified persons with FH, with more than 18 
500 person-years of follow-up, risks of cerebrovascular disease and ischemic stroke 
were not increased compared to the age, sex and calendar year adjusted Norwegian 
population, despite the previously reported higher risk of CHD in this cohort. Our 
results raise new questions regarding the specific role of LDL-cholesterol in 
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Table 1. Standardized incidence ratios (SIRs) for cerebrovascular disease and ischemic strokes 
in persons with familial hypercholesterolemia. 
 






rate per 1000 





SIR (95% CI)* 
Cerebrovascular 
disease (N=3144) 
      
 Women  19 9.7 2.0 (1.2-3.1) 21.6 0.9 (0.6-1.4) 
 Men  27 8.5 3.2 (2.2-4.6) 23.2 1.2 (0.8-1.7) 
 Total  46 18.3 2.5 (1.9-3.4) 44.8 1.0 (0.8-1.4) 
Ischemic stroke 
(N=3166) 
      
 Women 9 9.8 0.9 (0.5-1.8) 12.1 0.8 (0.4-1.5) 
 Men 17 8.6 2.0 (1.2-3.2) 13.6 1.3 (0.8-2.1) 
 Total 26 18.4 1.4 (1.0-2.1) 25.1 1.0 (0.7-1.5) 
* SIR=Standardized incidence ratio obtained using indirect standardization. CI=Confidence interval.  
 
 
 
 
 
 
 
 
 
 
